Tags

Type your tag names separated by a space and hit enter

The effects of Lyprinol(®) on delayed onset muscle soreness and muscle damage in well trained athletes: a double-blind randomised controlled trial.
Complement Ther Med. 2011 Dec; 19(6):311-8.CT

Abstract

OBJECTIVES

The aim of the study was to determine if Lyprinol(®) is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).

DESIGN

A double blind randomised placebo controlled trial.

SETTING

Twenty well trained male volunteers, matched by VO(2max) were randomly assigned to consume 200mg of Lyprinol(®) or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.

MAIN OUTCOME MEASURES

Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run).

RESULTS

No statistically significant differences were identified in any parameters between the active and placebo groups at any time point.

CONCLUSION

After 2 months ingestion of Lyprinol(®) at the currently recommended dosage (200mg/day) and a demanding eccentric exercise intervention, Lyprinol(®) did not convincingly affect DOMS and indicators of muscle damage.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Pumpa KL
National Institute of Sport Studies, University of Canberra, Australia. Kate.Pumpa@canberra.edu.au
Fallon KE
No affiliation info available
Bensoussan A
No affiliation info available
Papalia S
No affiliation info available

MeSH

AdolescentAdultAnimalsAthletic PerformanceBivalviaCreatine KinaseDouble-Blind MethodHumansInflammation MediatorsLipidsMaleMovementMuscle, SkeletalMusculoskeletal DiseasesMusculoskeletal PainMyoglobinOxygen ConsumptionPain MeasurementRunningTreatment OutcomeYoung Adult

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22036523

Citation

Pumpa, Kate L., et al. "The Effects of Lyprinol(®) On Delayed Onset Muscle Soreness and Muscle Damage in Well Trained Athletes: a Double-blind Randomised Controlled Trial." Complementary Therapies in Medicine, vol. 19, no. 6, 2011, pp. 311-8.
Pumpa KL, Fallon KE, Bensoussan A, et al. The effects of Lyprinol(®) on delayed onset muscle soreness and muscle damage in well trained athletes: a double-blind randomised controlled trial. Complement Ther Med. 2011;19(6):311-8.
Pumpa, K. L., Fallon, K. E., Bensoussan, A., & Papalia, S. (2011). The effects of Lyprinol(®) on delayed onset muscle soreness and muscle damage in well trained athletes: a double-blind randomised controlled trial. Complementary Therapies in Medicine, 19(6), 311-8. https://doi.org/10.1016/j.ctim.2011.08.004
Pumpa KL, et al. The Effects of Lyprinol(®) On Delayed Onset Muscle Soreness and Muscle Damage in Well Trained Athletes: a Double-blind Randomised Controlled Trial. Complement Ther Med. 2011;19(6):311-8. PubMed PMID: 22036523.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of Lyprinol(®) on delayed onset muscle soreness and muscle damage in well trained athletes: a double-blind randomised controlled trial. AU - Pumpa,Kate L, AU - Fallon,Kieran E, AU - Bensoussan,Alan, AU - Papalia,Shona, Y1 - 2011/09/15/ PY - 2010/09/02/received PY - 2011/08/21/revised PY - 2011/08/22/accepted PY - 2011/11/1/entrez PY - 2011/11/1/pubmed PY - 2012/2/18/medline SP - 311 EP - 8 JF - Complementary therapies in medicine JO - Complement Ther Med VL - 19 IS - 6 N2 - OBJECTIVES: The aim of the study was to determine if Lyprinol(®) is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS). DESIGN: A double blind randomised placebo controlled trial. SETTING: Twenty well trained male volunteers, matched by VO(2max) were randomly assigned to consume 200mg of Lyprinol(®) or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS. MAIN OUTCOME MEASURES: Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run). RESULTS: No statistically significant differences were identified in any parameters between the active and placebo groups at any time point. CONCLUSION: After 2 months ingestion of Lyprinol(®) at the currently recommended dosage (200mg/day) and a demanding eccentric exercise intervention, Lyprinol(®) did not convincingly affect DOMS and indicators of muscle damage. SN - 1873-6963 UR - https://wwww.unboundmedicine.com/medline/citation/22036523/The_effects_of_Lyprinol_��__on_delayed_onset_muscle_soreness_and_muscle_damage_in_well_trained_athletes:_a_double_blind_randomised_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0965-2299(11)00110-5 DB - PRIME DP - Unbound Medicine ER -